Skip to content

Aurinia Pharmaceuticals AUPH Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Abbott logo
AbbottABT

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's remainder of fiscal year 2024?
Aurinia Pharmaceuticals (AUPH) reported remainder of fiscal year 2024 of $879K in Q1 2026.
How has Aurinia Pharmaceuticals's remainder of fiscal year 2024 changed year-over-year?
Aurinia Pharmaceuticals's remainder of fiscal year 2024 increased by 2.6% year-over-year, from $857K to $879K.